Evogene (EVGN) Total Liabilities (2016 - 2026)
Evogene (EVGN) posted Total Liabilities of $9958.0 for Q1 2026, down 99.88% sequentially from $8.1 million in Q4 2025, and down 99.95% YoY from $21.9 million in Q1 2025.
Evogene (EVGN) Total Liabilities (2016 - 2026) Analysis & Trends
Evogene has reported Total Liabilities for 11 years, with the latest figure at $9958.0 in Q1 2026.
- Quarterly Total Liabilities fell 99.95% year-over-year to $9958.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9958.0 (down 99.95% YoY) and the FY2025 annual result came in at $8.1 million, down 67.75% from the prior year.
- Total Liabilities slipped to $9958.0 in Q1 2026 per EVGN's latest filing, from $8.1 million in the prior quarter.
- Over five years, Total Liabilities peaked at $56.7 million in Q2 2022 and troughed at $9958.0 in Q1 2026.
- A 5-year average of $28.6 million and a median of $22.4 million in 2023 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2024 and 2026: Total Liabilities gained 11.64% in 2024, then sank 99.95% in 2026.
- Over 5 years, Total Liabilities stood at $56.1 million in 2022, then tumbled by 60.06% to $22.4 million in 2023, then grew by 11.64% to $25.0 million in 2024, then sank by 67.75% to $8.1 million in 2025, then plunged by 99.88% to $9958.0 in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $9958.0, $8.1 million, and $8.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 10.03 Bn |
| 10 | Evogene | 4.38 Mn | 4.38 Mn | 204,000.00 | 9,958.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9,958.00 |
| Dec 31, 2025 | 8.07 Mn |
| Sep 30, 2025 | 8.83 Mn |
| Jun 30, 2025 | 21.55 Mn |
| Mar 31, 2025 | 21.91 Mn |
| Dec 31, 2024 | 25.03 Mn |
| Jun 30, 2024 | 40.97 Mn |
| Dec 31, 2023 | 22.42 Mn |
| Jun 30, 2023 | 53.34 Mn |
| Dec 31, 2022 | 56.13 Mn |
| Jun 30, 2022 | 56.66 Mn |
| Dec 31, 2021 | 76.30 Mn |
| Jun 30, 2021 | 87.54 Mn |
| Dec 31, 2020 | 71.92 Mn |
| Jun 30, 2020 | 61.11 Mn |
| Dec 31, 2019 | 71.36 Mn |
| Dec 31, 2018 | 58.69 Mn |
| Dec 31, 2017 | 77.60 Mn |
| Dec 31, 2016 | 95.99 Mn |